FDA Alert: Abiomed Impella Blood Pump Urgent Recall

Controller may fail to detect the Impella device

Abiomed Impella blood pump controllers

Controller May Fail to Detect Device

Abiomed has issued an urgent safety notice for its Automated Impella Controller (AIC) due to a potentially serious issue where the system may fail to detect the Impella blood pump when connected.

This malfunction could result in inadequate cardiac support, which is especially dangerous for patients in cardiogenic shock.

Affected Products, Product Codes, UDI-DIs, and Serial Numbers (click on the link to download a list.)

Key Details

  • Issue: The controller may not recognize the connected pump during startup or transfer between consoles.
  • No visual alarm appears on screen to indicate a problem.
  • Reported Cases: 3 patient deaths have been linked to this issue as of June 13; no serious injuries reported.
  • Impacted Devices: All AICs across the Abiomed Impella pump line.

Recommended Actions

  • Always have a backup AIC available.
  • If the pump isn’t detected within 20 seconds:
    • Switch back to the previous console.
    • Reboot the non-responsive console.
    • Start the case on a different AIC if needed.
  • Distribute this alert to all relevant clinical staff and facilities.
  • Forward notice to any facility that received affected products.

Why It Matters

Failure to detect the pump could lead to delayed or absent hemodynamic support, putting critically ill patients at high risk.

For questions or to report adverse events, contact Abiomed at (978) 646-1400.

The FDA is actively reviewing this high-risk issue and will provide updates here as more information becomes available.

Read more about Mechanical Circulatory Support (MCS) devices

Exposure to toxic materials during hemodialysis and dialysis

FDA announcement The US Food and Drug Administration (FDA) issued an announcement on March 7 to update its May 2022 letter to healthcare providers regarding the potential risks of exposure to toxic compounds when using hemodialysis and peritoneal dialysis. This update...

FDA Breakthrough Devices Program

Program assists needed products with access to US market The U.S. Food and Drug Administration (FDA) has established the Breakthrough Devices Program, a voluntary program that aims to expedite the development, assessment, and review of medical devices that demonstrate...

Approvals for FDA Breakthrough Devices

Innovative Devices for Unmet Needs The Food and Drug Administration (FDA) has made a positive decision on the marketing applications of the following products. What sets them apart? They are innovative devices that qualified and participated in FDA's Breakthough...